Current status of HTRF® technology in kinase assays

Expert Opinion on Drug Discovery

Volumn 3, Issue 12, 2008, Pages 1461-1474

  Jia, Yong ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

Assay; Europium cryptate; FRET; HTRF; Kinase; Phospho specific antibodies; SAXL

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; DORAMAPIMOD; EUROPIUM;

BINDING KINETICS; CELL ASSAY; COMPETITIVE INHIBITION; DRUG BINDING; DRUG SCREENING; ENZYME ASSAY; ENZYME MECHANISM; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HOMOGENOUS TIME RESOLVED FLUORESCENCE RESONANCE ENERGY TRANSFER; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL DETECTION; STRUCTURE ACTIVITY RELATION;

EID: 58049217116     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440802518171     Document Type: Review

References (53)

1. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34
2. Hunter T. Signaling - 2000 and beyond. Cell 2000;100:113-27
3. Mazitschek R, Giannis A. Inhibitors of angiogenesis and cancer related receptor tyrosine kinases. Curr Opin Chem Biol 2004;8:432-41
4. Myers MR, He W, Hulme C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr Pharm Des 1997;3:473-502
5. Vlahos CJ, McDowell SA, Clerk A. Kinases as therapeutic targets for heart failure. Nat Rev Drug Discov 2003;2:99-113
6. Resnick L, Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov Today 2004;9:932-9
7. Cohen P. The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol 1999;3:459-65
8. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-15
9. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 2003;36:462-9
10. Jia Y, Quinn CM, Kwak S, Talanian RV. Current in vitro kinase assay technologies: the quest for a universal format. Curr Drug Discov Technol 2008;5:59-69
11. von Ahsen O, Bömer U. High-throughput screening for kinase inhibitors. ChemBioChem 2005;6:481-90
12. Sittampalam GS, Kahl SD, Janzen WP. High-throughput screening: advances in assay technologies. Curr Opin Chem Biol 1997;1:384-91
13. Minor L. Assays for membrance tyrosine kinase receptors: methods for high-throughput screening and utility for diagonistics. Expert Rev Mol Daign 2005;5:561-71
14. Zaman GJR, Garritsen A, de Boer Th, van Boeckel CAA. Fluorescence assays for high-throughput screening of protein kinases. Comb Chem High Throughput Screen 2003;6:313-20
15. Hemmilä I. LANCETM: homogeneous assay platform for HTS. J Biomol Screen 1999;4:303-307
16. Degorce F. HTRF®: pioneering technology for high-throughput screening. Expert Opin Drug Discov 2006;1:753-64
17. Bazin H, Trinquet E, Mathis G. Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions. Rev Mol Biotechnol 2002;82:233-50
18. Bazin H, Préaudat M, Trinquet E, Mathis G. Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptate as a tool for probing molecular interactions in biology. Spectrochim Acta A Mol Biomol Spectrosc 2001;57:2197-211
19. Mathis G. Probing molecular interactions with homogeneous techniques bases on rare earth cryptate and fluorescence energy transfer. Clin Chem 1995;41:1391-7
20. Mathis G. Rare earth cryptate and homogeneous fluoroimmunoassays with human sera. Clin Chem 1993;39:1953-9
21. Mathis G. HTRF® technology. J Biomol Screen 1999;4:309-13
22. Kolb JM, Yamanaka G, Manly SP. Use of a novel homogeneous fluorescent technology in high throughput screening. J Biomol Screen 1996;1:203-10
23. Cummings RT, McGovern HM, Zheng S, et al. Use of a phosphotyrosine-antibody pair as a general detection method in homogeneous time-resolved fluorescence: application to human immunodeficiency viral protease. Anal Biochem 1999;269:79-93
24. Preaudat M, Ouled-Diaf J, Alpha-Bazin B, et al. A homogeneous caspase-3 activity assay using HTRF® technology. J Biomol Screen 2002;7:267-74
25. Leblanc V, Delaunay V, Lelong JC, et al. Homogeneous time-resolved fluorescence assay for identifying p53 interactions with its protein partners, directly in a cellular extract. Anal Biochem 2002;308:247-54
26. Maurel D, Kniazeff J, Mathis G, et al. Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. Anal Biochem 2004;329:253-62
27. Beasley JR, McCoy PM, Walker TL, Dunn DA. Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunnoassays. Assay Drug Dev Technol 2004;2:141-51
28. Schaefer EM, Guimond S. Detection of protein kinase activity using a high-capacity streptavidin-coated membrane and optimized biotinylated peptide substrate. Anal Biochem 1998;261:100-12
29. Moshinsky DJ, Ruslim L, Blake RA, Tang F. A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype. J Biomol Screen 2003;8:447-52
30. Klumpp M, Boettcher A, Becker D, et al. Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. J Biomol Screen 2006;11:617-33
31. Park Y-W, Cummings RT, Wu L, et al. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. Anal Biochem 1999;269:94-104
32. von Ahsen O, Schmidt A, Klotz M, Parczyk K. Assay concordance between SPA and TR-FRET in high-throughput screening. J Biomol Screen 2006;11:606-16
33. Ohml N, Wingfield JM, Yazawa H, Inagaki O. Development of a homogeneous time-resolved fluorescence assay for high-throughput screening to identify Lck inhibitors: comparison with scintillation proximity assay and streptavidin-coated plate assay. J Biomol Screen 2000;5:463-70
34. Newman M, Josiah S. Utilization of fluorescence polarization and time resolved fluorescence resonance energy transfer assay formats for SAR studies: Src kinase as a model system. J Biomol Screen 2004;9:525-32
35. JiaY, Quinn CM, Bump N, et al. Purification and kinetic characterization of recombinant human mitogen-activated protein kinase kinase kinase COT and the complexes with its cellular partner NF-Κ:B1 p105. Arch Biochem Biophy 2005;441:64-74
36. Jia Y, Quinn CM, Clabbers A, et al. Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization. Anal Biochem 2006;350:268-76
37. Jia Y, Quinn CM, Talanian RV. Designing in vitro assays for drug discovery: a study with the human MAP3 kinase COT. Expert Opin Drug Discov 2007;2:909-15
38. Jia Y, Quinn CM, Gagnon AI, Talanian R. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem 2006;356:273-81
39. Harbert C, Marshall J, Soh S, Steger K. Development ofa HTRF® kinase assay for determination of Syk activity. Curr Chem Genomics 2008;1:20-6
40. Ross H, Armstrong CG, Cohen P. A non-radioactive method for the assay of many serine/threonine-specific protein kinases. Biochem J 2002;366:977-81
41. Lowery RG, Kleman-Leyer K. Transcreener™: screening enzymes involved in covalent regulation. Expert Opin Ther Targets 2006;10:179-90
42. Huss KL, Blonigen PE, Campbell RM. Development of a Transcreenerô kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J Biomol Screen 2007;12:578-84
43. Maira S-M, Voliva C, Garcia-Echeverria C. Class IA phosphatidylinositol 3-kinase: from their biological implication in human cancers to drug discovery. Expert Opin Ther Targets 2008;12:223-38
44. Rommel C, Camps M, Ji H. PI3Kd and PI3Kg: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007;7:191-201
45. Carpenter CL, Duckworth BC, Auger KR, et al. Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 1990;265:19704-11
46. Mullinax TR, Henrich G, Kasila P, et al. Monitoring inositol-specific phospholipase C activity using a phospholipid FlashPlate™. J Biomol Screen 1999;4:151-5
47. Fuchikami K, Togame H, Sagara A, et al. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase γ. J Biomol Screen 2002;7:441-50
48. Gray A, Olsson H, Batty IH, et al. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 2003;313:234-45
49. Robers MB, Horton RA, Bercher MR, et al. High-throughput cellular assays for regulated posttranslational modifications. Anal Biochem 2008;372:189-97
50. Adams DG, Wang Y, Mak PA, et al. Cellular Ser/Thr kinase assays using generic peptide substrates. Curr Chem Genomics 2008;1:54-64
51. Osmond RW, Sheehan A, Borowicz R, et al. GPCR screening via ERK1/2: a novel platform for screening G protein-coupled receptors. J Biomol Screen 2005;10:730-7
52. Warner G, Illy C, Pedro L, et al. AlphaScreen kinase HTS platforms. Curr Med Chem 2004;11:721-30
53. Jia Y, Gu X-J, Brinker A, et al. Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Expert Opin Drug Doscov 2008;3:959-78